Tous Actualités
Suivre
Abonner Resverlogix Corp.

Resverlogix Corp.

Industry Leaders Select Resverlogix's RVX-208 Among Top 10 Most Promising Drugs

Calgary, Canada (ots/PRNewswire)

Resverlogix Corp's
("Resverlogix" or the "Company") (TSX:RVX) novel lead  ApoA-I drug
candidate, RVX-208 has been selected as one of the top 10 most
promising cardiovascular disease (CVD) drugs available for strategic
partnering by an independent committee assembled by Windhover
Information, a  leading provider of business information products and
services to senior  executives in the pharmaceutical, biotechnology,
and medical device  industries.
"We are honored to be part of this select group of top ten most
promising  innovative drugs," stated Donald McCaffrey, President and
CEO of Resverlogix.  "It again validates RVX-208 and our entire
NexVas(TM) PR franchise as an  important new small molecule drug for
the largest market with unmet needs,  atherosclerosis and
cardiovascular diseases. We are moving towards our next  important
milestone, Phase 1b/2a, later this fall and continue to measure
safety, tolerability and key reverse cholesterol transport (RCT)
markers such  as ApoA-I, pre-beta HDL, HDL and cholesterol efflux."
The selection committee was led by Marc Wortman, PhD,
contributing writer  to Windhover's IN VIVO and Start Up
publications, and Michael Rice, Senior  Consultant, and Ed Saltzman,
President of Defined Health, a leading business  development strategy
consulting firm. Drawing on the analytic resources of  these
organizations, the group evaluated hundreds of compounds currently in
development for the treatment of cardiovascular disease prior to
selecting  RVX-208 among the top ten most attractive drug available
for partnering.
"Selected companies have been screened using a strict set of
judging  criteria for the Top 10 award, and represent what our
committee considered  the most attractive cardiovascular
opportunities the industry has to offer,"  stated Roger Longman,
Managing Director of Windhover Information. "Winners  have met strict
criteria including: unmet medical need, market potential,  diversity
of indications, strong science, multi-level partnering  opportunities
(biotech and pharma), potential for new opportunities beyond  initial
indications, history of the molecule and drug and be a strong
company."
"To have a highly regarded selection committee realize the
commercial  potential for RVX-208 is important for us," stated
Kenneth Lebioda, Senior  Vice President of Business and Corporate
Development at Resverlogix.  "Atherosclerosis, the leading underlying
cause of cardiovascular death,  represents the largest cost center to
health systems globally. Novel small  molecules that enhance ApoA-I
production have a diverse number of patient  groups that they can
help such as low HDL, acute coronary syndrome, diabetes,  post
myocardial infarction and Alzheimer's. A novel drug that could help
these diseases will have a major positive impact on patients and
health  systems alike. This is where RVX-208 offers an unrivalled
commercial  opportunity for the life science industry," added Mr.
Lebioda.
As a selected company, Resverlogix has been invited to present
data on  RVX-208 at Windhover's Therapeutic Area Partnerships
conference on November  3-5, 2008 in Philadelphia.
About Windhover
Windhover Information Inc., an Elsevier company, has led the
field in  providing analysis of the healthcare industry to
decision-makers at all  levels since the founding of its flagship
publication, IN VIVO, The Business  & Medicine Report, in 1983.
Windhover provides its information and analysis  in many formats,
including print, electronic databases, international  conferences and
webinars. For more on the company's products and services,  please
see http://www.windhover.com.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in
the  development of novel therapies for important global medical
markets with  significant unmet needs. The NexVas(TM) program is the
Company's primary  focus which is to develop novel small molecules
that enhance ApoA-I. These  vital therapies address the grievous
burden of atherosclerosis and other  important diseases such as acute
coronary syndrome, diabetes, Alzheimer's  and other vascular
disorders. The Company's secondary focus is TGF-Beta  Shield(TM), a
program that aims to address burgeoning grievous diseases,  such as
cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock
Exchange (TSX:RVX). For further information please visit
http://www.resverlogix.com.
This news release may contain certain forward-looking statements
that  reflect the current views and/or expectations of Resverlogix
Corp. with  respect to its performance, business and future events.
Such statements are  subject to a number of risks, uncertainties and
assumptions. Actual results  and events may vary significantly. The
TSX Exchange does not accept  responsibility for the adequacy or
accuracy of this news release.
For further information: Theresa Kennedy, VP, Corporate
Communications,  Resverlogix Corp., Phone: +1-604-538-7072, Fax:
+1-403-256-8495, Email:   Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations,  Resverlogix Corp., Phone:
+1-403-254-9252, Fax: +1-403-256-8495, Email:   Sarah@resverlogix.com,
Website: http://www.resverlogix.com (RVX.)

Contact:

For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax:
+1-403-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations, Resverlogix Corp., Phone:
+1-403-254-9252, Fax: +1-403-256-8495, Email: Sarah@resverlogix.com

Plus de actualités: Resverlogix Corp.
Plus de actualités: Resverlogix Corp.
  • 18.06.2008 – 20:22

    Key Primary Resverlogix Objective Obtained

    San Diego, California and Calgary, Canada (ots/PRNewswire) - - Findings Demonstrate Clear Trends of Proof of Principle of Reverse Cholesterol Transport in Human Volunteers SAN DIEGO, California and CALGARY, Canada, June 18 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today that it has completed the planned exploratory efficacy analysis of the data from the Phase I, 7 ...

  • 22.04.2008 – 15:36

    Dosing for RVX-208 Phase 1a Clinical Study Completed

    Calgary, Canada (ots/PRNewswire) - - Phase 1a Study Objectives Were Met - TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has completed dosing of its Phase 1a safety, tolerability and pharmacokinetics study for its lead drug candidate, RVX-208, which addresses the dyslipidemia market. "Initial results from the emerging data are very good," ...

  • 14.01.2008 – 17:15

    Progress Report from RVX-208 Phase 1 Clinical Study

    Calgary, Canada (ots/PRNewswire) - - Resverlogix Sees Early Success and Expedites Phase 2 Plans TSX Exchange Symbol: RVX Resverlogix is pleased to announce preliminary data from the RVX-208 Phase 1 safety and pharmacokinetics study. Forty healthy volunteers have so far been treated of which sixteen have received multiple doses. As anticipated from the extensive Investigational New Drug toxicology studies no ...